Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AVB-S6-500 |
| Synonyms | |
| Therapy Description |
AVB-S6-500 is a fusion protein comprised of human IgG1 linked to the extracellular domain of Axl, which binds to growth arrest-specific protein 6 (GAS6), potentially resulting in decreased downstream signaling and reduced tumor growth (PMID: 32148495, PMID: 31599479). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AVB-S6-500 | AVBS6500|AV S6 500|Batiraxcept|AVB-500|RUGA-S6 | AVB-S6-500 is a fusion protein comprised of human IgG1 linked to the extracellular domain of Axl, which binds to growth arrest-specific protein 6 (GAS6), potentially resulting in decreased downstream signaling and reduced tumor growth (PMID: 32148495, PMID: 31599479). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05826015 | Phase I | AVB-S6-500 AVB-S6-500 + Paclitaxel | AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Withdrawn | 0 |